Skip to search.
 Dow Down 0.60% Nasdaq Down 0.07%

Forest Laboratories Inc. (FRX)

-NYSE

33.38 Up 0.05(0.15%) May 25, 4:00PM EDT|After Hours: 33.38 0.00 (0.00%) May 25, 4:28PM EDT

ProfileGet Profile for:
Forest Laboratories Inc.
909 Third Avenue
New York, NY 10022-4731
United States - Map
Phone: 212-421-7850
Fax: 212-750-9152
Website: http://www.frx.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Drug Manufacturers - Other
Full Time Employees:N/A

Business Summary 

Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products. Its principal products include Lexapro for the treatment of major depressive disorder in adults and adolescents, and generalized anxiety disorder in adults; Namenda for the treatment of moderate and severe Alzheimer's disease; Bystolic for the treatment of hypertension; Savella for the management of fibromyalgia; and Teflaro, a hospital-based injectable cephalosporin antibiotic for the treatment of adults with community-acquired bacterial pneumonia. The company is also developing various products, including Linaclotide that is in Phase III clinical trials for the treatment of constipation-predominant irritable bowel syndrome and chronic constipation; Aclidinium, which is in Phase III clinical trials for the treatment of chronic obstructive pulmonary disease (COPD); and Cariprazine that is in Phase III clinical trials for the treatment of schizophrenia, bipolar mania, and other psychiatric conditions. In addition, it is developing F2695, which is in Phase III clinical trials for the treatment of depression; Avibactam, a beta-lactamase inhibitor that is in Phase II clinical trials; GRT 6005, which completed Phase II clinical trials for the treatment of moderate to severe chronic pain; TTP399 that completed Phase I clinical trial for the treatment of Type II diabetes; mGLuR1/5 Compounds for the treatment of anxiety, depression, and other central nervous system conditions; and LAS100977 that is in Phase II clinical trials for the treatment of asthma and COPD. Forest Laboratories, Inc. sells its products through its sales forces and independent distributors to physicians, pharmacies, hospitals, and managed care and other healthcare organizations. The company was founded in 1956 and is based in New York, New York.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Forest Laboratories Inc.

Corporate Governance 
Forest Laboratories Inc.’s Governance Risk Indicator (GRI®) as of May 1, 2012 is: Audit (Low Concern), Board (Low Concern), Compensation (Medium Concern), Shareholder Rights (Low Concern).
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. Howard Solomon , 84
Chairman, Chief Exec. Officer and Pres
2.73M0.00
Mr. Francis I. Perier Jr., 52
Chief Financial Officer, Exec. VP of Fin. & Admin. and Member of Disclosure, Legal Compliance & Risk Management Committee
980.00K0.00
Ms. Elaine Hochberg , 55
Chief Commercial Officer, Exec. VP of Marketing and Member of Disclosure, Legal Compliance & Risk Management Committee
1.07M0.00
Dr. Marco Taglietti M.D., 52
Sr. VP of R&D, Member of Disclosure, Legal Compliance & Risk Management Committee and Pres of Forest Research Institute (FRI)
884.00K0.00
Mr. David Solomon ,
Sr. VP of Corp. Devel. & Strategic Planning
629.00K0.00
Amounts are as of Dec 30, 2011 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders